ArticleScience China. Life sciences2022

CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.

Jiang Chen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.